Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Staging classification of aortic stenosis based on the extent of cardiac damage EUROPEAN HEART JOURNAL Genereux, P., Pibarot, P., Redfors, B., Mack, M. J., Makkar, R. R., Jaber, W. A., Svensson, L. G., Kapadia, S., Tuzcu, E., Thourani, V. H., Babaliaros, V., Herrmann, H. C., Szeto, W. Y., Cohen, D. J., Lindman, B. R., McAndrew, T., Alu, M. C., Douglas, P. S., Hahn, R. T., Kodali, S. K., Smith, C. R., Miller, D., Webb, J. G., Leon, M. B. 2017; 38 (45): 3351-+

Abstract

In patients with aortic stenosis (AS), risk stratification for aortic valve replacement (AVR) relies mainly on valve-related factors, symptoms and co-morbidities. We sought to evaluate the prognostic impact of a newly-defined staging classification characterizing the extent of extravalvular (extra-aortic valve) cardiac damage among patients with severe AS undergoing AVR.Patients with severe AS from the PARTNER 2 trials were pooled and classified according to the presence or absence of cardiac damage as detected by echocardiography prior to AVR: no extravalvular cardiac damage (Stage 0), left ventricular damage (Stage 1), left atrial or mitral valve damage (Stage 2), pulmonary vasculature or tricuspid valve damage (Stage 3), or right ventricular damage (Stage 4). One-year outcomes were compared using Kaplan-Meier techniques and multivariable Cox proportional hazards models were used to identify 1-year predictors of mortality. In 1661 patients with sufficient echocardiographic data to allow staging, 47 (2.8%) patients were classified as Stage 0, 212 (12.8%) as Stage 1, 844 (50.8%) as Stage 2, 413 (24.9%) as Stage 3, and 145 (8.7%) as Stage 4. One-year mortality was 4.4% in Stage 0, 9.2% in Stage 1, 14.4% in Stage 2, 21.3% in Stage 3, and 24.5% in Stage 4 (Ptrend?

View details for PubMedID 29020232